Vir Advances HBV, Flu Programs While Focused On COVID-19
Company Brought In Significant Cash Before And After Its IPO
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
You may also be interested in...
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.